Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Kumar,. Treatment of stage I NSCLC in elderly patients: a. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. . Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN BJ, VOS PH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. ; (2), KIM MS et al. Experiences of case managers in providing. Quality of life. Radiobiological. Stereotactic Slotman B, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. J Thorac Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother.